Objective To explore the impact of the centralized procurement policy(CPP)on the medical consumables industry,in particular the market of coronary stents,based on the real-world data in a tertiary hospital in Beijing and the publicly available annual reports of the listed bidders.Methods The market concentration of coronary stents was compared before(from January 2019 to December 2020)and after(from January 2021 to December 2022)the implementation of CPP by using the Herfindahl-Hirschman Index(HHI).The market shares and mean prices of domestic and imported coronary stents as well as the product scope,business incomes,and R&D expenses of the listed bidders in the cardiovascular intervention product lines were compared.With the enterprise category(domestic/imported),enterprise type,and price decline as variables,the most relevant factors of product shares were identified by using the grey correlation analysis.Results The market concentration of coronary stents increased after the adoption of CCP.The mean prices significantly differed between domestic and imported coronary stents before the implementation of CCP(P＜0.01)but showed no significant difference after the implementation(P＞0.05).The use of imported coronary stents significantly increased,and more cardiovascular interventional product types were used.The enterprise category was the most relevant factor affecting the market share.Conclusion Enterprise competitiveness can be raised by strengthening product R&D,enriching product lines,and expanding business areas.A multi-level financing system may provide essential financial support for the medical consumables industry.Deepening international cooperation and global operations can help enterprises mitigate risks and promote sustainable development in the industry.
维普
万方数据